Oral Antidiabetic Agents

Abstract

Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or...

In vitro health beneficial activities of Pumpkin seeds from Cucurbita moschata cultivated in Lemnos

“…This causes a reduction in the rate of glucose absorption and consequently blunts the postprandial blood glucose and insulin levels. Thus alpha-glucosidase inhibitors may be an attractive therapeutic modality in type II diabetic patients (Bischoff, 1994;Jiang & Du, 2011;Krentz & Bailey, 2005;Lin et al, 2011;Oboh & Ademosun, 2011).…”

Anti-diabetic Effects of New Herbal Formula in Neonatally Streptozotocin-Induced Diabetic Rats

“…6) Traditional herbal medicine has been widely used for disease treatment and is recognized as an interesting alternative to conventional medicine. [7][8][9] The uncertainty about the efficacy and safety of the currently available oral hypoglycemic drugs has prompted a search for safer and more effective agents in the treatment of diabetes. 8) A wide variety of the traditional herbal remedies being used by diabetic patients, especially in the third world countries, 9) and may, therefore, represent new avenues in the search for alternative hypoglycemic drugs.…”

Potential nutritional strategies for the amelioration or prevention of high rigor temperature in cattle – a review

“…Thiazolidinediones are potent, synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARg) that potentiate the action of insulin in peripheral tissues, and are used as orally active treatments for diabetes in humans (Krentz and Bailey 2005). Kushibiki et al (2001) administered TZD to steers injected with TNF-a to induce insulin resistance and observed a decrease in plasma concentrations of NEFA, insulin and glucagon, suggesting that administration of TZD ameliorated insulin action.…”